Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
- SABMiller Rejects GBP 42.15/Share Offer From AB InBev SA (BUD)
- Futures up as oil prices rise for fourth day
- Yum! Brands (YUM) Misses Q3 EPS by 7c; Cuts FY15 EPS Growth Outlook
- Prince Alwalled Bin Talal Shows New 5.17% Stake in Twitter, Inc. (TWTR)
- Adobe Systems (ADBE) Offers 3-Year Growth Strategy; Guides FY16 EPS, Revenue Below Views
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Places Clinical Hold on Advaxis' (ADXS) Axalimogene Filolisbac IND Application
- Opexa Therapeutics (OPXA) Granted Four Patents Covering T-Cell Immunotherapy Platform
- Otonomy (OTIC) Holds Investor Day, Offers Review of OTIPRIO
Create E-mail Alert Related CategoriesFDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!